Clinical Trial Update: Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the efficacy of adding dupilumab to medium-dose ICS/LABA versus escalating to high-dose ICS/LABA in adolescents and adults w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Dupilumab (dupilumab)
• Inhaled corticosteroid + long-acting beta-agonist (ICS+LABA) combination therapy (inhaled corticosteroid + long-acting beta-agonist)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Asthma | Phase 4 | Status: RECRUITING